INTRODUCTION
Iron is an essential nutrient, that is required by all organisms for basic cellular functions including oxidative metabolism and DNA synthesis. Vertebrates also require iron as a component of the oxygen carrying molecule, hemoglobin. While it is necessary for life, iron is invariably toxic in excess. Hence, its absorption must be strictly regulated. Iron deficiency is manifest primarily by anemia resulting from insufficiency of iron for hemoglobin production. Iron deficiency anemia affects an estimated 600 million individuals worldwide, primarily women and young children. While iron deficiency anemia is most often due to dietary insufficiency, an interesting subset of patients have inherited defects in iron transport.
At the other extreme, hemochromatosis is a disease of iron accumulation, resulting from inappropriately increased absorption of dietary iron. There are two prevalent genetic forms of hemochromatosis. Hereditary hemochromatosis is the most common genetic disease of individuals of Northern European descent. Approximately one in ten individuals in that population carry at least one copy of a mutant gene, dubbed HFE [1] . Heterozygotes have subclinical iron loading, and untreated homozygotes accumulate up to ten times normal body iron stores by middle age. Without intervention, iron toxicity leads to failure of the liver, heart and endocrine organs. African iron overload affects many individuals in the sub-Saharan portion of the African continent. This disease is similar to hereditary hemochromatosis, though the pattern of iron deposition differs slightly. African iron overload appears to have a genetic basis [2] , but it is unlinked to HFE, and the responsible gene has not been mapped.
Despite the prevalence and severity of these disorders, iron transport remains poorly understood. Figure 1 There is no physiologic mechanism for the excretion of iron in mammals; iron leaves the body through sloughing of mucosal cells and loss of blood. Iron balance is regulated, therefore, strictly at the level of absorption. Women absorb more iron than men, to compensate for regular menstrual blood loss. On the serosal side of the enterocyte iron is quickly bound to the chelator protein, transferrin, to enter the transit compartment. Chelation detoxifies iron by making it less reactive. Diferric transferrin delivers iron to the storage compartment, which primarily consists of hepatic ferritin, and to the major sites of use, most notably the erythroid bone marrow. Little is known of how iron enters or leaves hepatic cells, though it is clear that it must be removed from transferrin, and it must remain in an exchangeable form.
Iron entry into the erythron is partially explained by an endocytotic process termed the transferrin cycle. Diferric transferrin binds to specific receptors on the surface of erythroid precursors, and the ligand-receptor complex is endocytosed to form specific endosomes. Next, endosomes are acidified through the action of a proton pump, leading to iron release. These steps have been elegantly described by Klausner, Lodish and their co-workers [reviewed in 3] . Apotransferrin and transferrin receptors are recycled back to the cell surface to repeat the cycle. The fate of the iron, however, is not well understood. Somehow iron must transit the lipid bilayer surrounding the endosome, to gain access to the cytoplasm and ultimately to the mitochondrion where it is incorporated into heme.
We would like to identify the molecules which transport iron across the membranes of the intestinal cell and the red cell. To do this, we have taken a novel genetic approach. The power of this approach becomes apparent from analysis of a patient, and a mutant 220 Andrews: Iron transport defects in mice mouse, which have identical phenotypes due to defects in iron transport. The patient will be presented briefly, and the mouse model will be discussed in detail.
IRON-RESISTANT IRON DEFICIENCY ANEMIA IN A TODDLER P.D. was referred to our center for evaluation of "iron-resistant iron deficiency anemia." He was the 4.3 kg product of a healthy mother born in Nigeria after an uncomplicated pregnancy. He did well during his first year and a half, but was noted to be pale at a routine 18 month well-child check. At that time he had a hemoglobin (Hgb)c of 7.0 g/dl ( Figure 2 .
In summary, this toddler presented as a well-appearing child with profound hypochromic, microcytic anemia unresponsive to oral iron therapy, and partially responsive to intravenous iron therapy. His anemia persisted after total body iron stores were repleted. Red cell morphology is consistent with severe iron deficiency, but the RBC count was surprisingly high. He appears to have defects in both intestinal iron transport, and red cell iron utilization. No genetic pattern can be discerned, because there is insufficient data. However, similar patients have been described previously by George Buchanan [41 and Kip Hartman [5] ; the inheritance in those patients appears to be autosomal recessive. [6] . Homozygous mk mice have hypochromic, microcytic anemia with red cell morphology which is indistinguishable from that of the patient, P.D., and a RBC count which is elevated out of proportion to their anemia [7] . These mice fail to respond to oral iron, and respond poorly to intravenous iron. Bone marrow transplantation experiments demonstrate defects at the level of intestinal absorption as well as bone marrow utilization [8] . We 
GENETIC LOCALIZATION OF mk
In the past five years, technical advances have had great impact on mouse genetics. Dinucleotide repeats of up to 100 basepairs in length (generally with the structure (CA)) are distributed randomly throughout mammalian genomes. These repeats, termed simple sequence length polymorphism markers or SSLPs, have a convenient property of low grade genetic instability. That is to say, they tend to remain constant in length within inbred mouse strains, but they often vary in length between mouse strains. As a result, they can be used as genetic markers. William Dietrich, Eric Lander, and their colleagues have described over seven thousand SSLP markers, and determined their positions on a high resolution genetic map of the mouse genome [9] . These markers form the framework upon which more precise genetic maps can be constructed. Analysis of these markers is carried out as shown schematically in Figure 3 .
To localize the mk gene precisely, we set up a large backcross breeding experiment. After nearly one hundred generations of inbreeding, the mice carrying the mk mutation are considered a distinct recombinant inbred strain, termed At the time of the symposium, we had analyzed 551 backcross animals. These data were used to generate a genetic map of the region surrounding mk, as shown in Figure 4 . The mk phenotype is flanked by two SSLP markers (Dl5Mit markers 14 and 77) towards the centromere, and one SSLP marker (DlSMit 97) towards the telomere. The entire candidate region was less than 0.4 centimorgans. A fourth marker, derived from the 3' untranslated region of a cDNA mapping to that region, was invariably linked to the phenotype, and showed no recombinations in the backcross panel. This was considered a potential candidate gene. We now have strong data indicating that that cDNA from the Nramp2 gene encodes the mk protein; those results will be published elsewhere.
Three genes known to map to mouse chromosome 15 encode proteins have features which led us to consider them as candidates for mk. Two transcription factors that have been shown to be important for red blood cell development, p45 NF-E2 [10] and CP2 [11] , are encoded by genes residing on the portion of human chromosome 12q which is syntenic with the mk region of mouse chromosome 15. Peters et al. previously suggested that p45 NF-E2 was the mk gene [12] , but this was later shown to be incorrect [13] [14] [15] . We have also ruled out CP2, based on more precise mapping.
A third gene, encoding the protein Rab5b, also maps to this region. Rab5b is a cytoplasmic ras-like protein, which co-localizes with the transferrin receptor in an endosomal compartment [16] . While 
CONCLUSIONS
The advent of high resolution chromosomal mapping in the mouse has greatly facilitated positional cloning efforts. We have taken advantage of this, to use a genetic approach to work out the details of iron transport pathways. Several spontaneous mouse mutants with defects in key transport steps have been characterized by mouse breeders. Their observable phenotype is hypochromic, microcytic anemia, resulting from insufficiency of iron for hemoglobin production. We are studying several of the most informative of these mutants. Microcytic anemia (mk) mice have poor absorption of dietary iron through the intestine, and poor uptake of plasma iron by red cell precursors, indicating both intestinal and hematopoietic cell defects. Hemoglobin deficit (hbd) mice have normal intestinal iron absorption, but defective red cell iron uptake. Flexed tail (f) mice have an isolated defect in red cell iron utilization, that causes them to form abnormal iron granules in the cytoplasm of red cell precursors. We plan to clone and characterize each of these defective genes. Our long term goal is to define all molecular steps in iron transport, from the intestine to the site of hemoglobin synthesis in the erythron. The mutant mice described above, and others yet to be studied, will be enormously instructive in this endeavor. Once key proteins have been identified, biochemical and genetic interaction studies should help identify other components of the pathways.
It is likely that iron transport mechanisms are similar among mammals, and that lessons learned from mice will lead to an understanding of human iron transport. A small group of Hematology Clinic patients, followed at Children's Hospital, have clinical features that are remarkably similar to the genetic iron transport disorders seen in mk, hbd and other mouse mutants. We will soon be in a position to test whether the human patients 224 Andrews: Iron transport defects in mice 225 have mutations in genes homologous to those affected in the mice. In the long term, we hope that improved understanding of iron transport will lead to novel therapies for iron deficiency and iron overload disorders.
